Top news of the week: 28.06.2022.
What We Saw at BIO: The Second Hurdle
More than 14,000 people attended the annual #BIO22 meeting in San Diego, meaning there are at least 14,000 versions of what happened. But unless you have the emotional intelligence of a ...
The rise of China’s VC-industrial complex
The state is reshaping one of the world’s biggest startup scenes—not necessarily for the better
Gates Foundation funds biotech company cataloging the viruses that infect bacteria
A Seattle DNA analysis startup is taking on a project with global ambitions with $5.5 million in new funds from the Bill & Melinda Gates Foundation and the U.S. National… Read More
Bruised investors focus on biotechs with drugs closer to market
Biotech investors nursing losses from stock price falls are now focusing on firms which are closer to getting their drugs to market, rather than those at the early stages of development.
Bringing Precision Medicine to Neuro: Ivana Magovcevic-Liebisch on The Long Run
Today’s guest on The Long Run is Ivana Magovcevic-Liebisch She is the CEO of Cambridge, Mass.-based Vigil Neuroscience. The story starts with Amgen. The big biotech made a strategic ...
Randall N. Hyer, MD, PhD, MPH, former Moderna executive, named president of the Baruch S. Blumberg Institute
Doylestown, Pa. – The Baruch S. Blumberg Institute’s Board of Directors has appointed Randall N. Hyer, MD, PhD, MPH, former senior vice president for global medical affairs at …
MISPRO ANNOUNCES NEW LOCATION IN WALTHAM BIOPHARMA CLUSTER Learn More
Coya Therapeutics: Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology From Carnegie Mellon University More Landos: Names Gregory Oakes …
Radius, maker of bone and cancer drugs, to be bought in take-private deal
Two investment firms, Gurnet Point Capital and Patient Square Capital, have agreed to pay as much as $890 million for Radius, which has come under pressure amid share price declines.